IP Library Granted Patent US 8,936,803
Granted Patent B2
US 8,936,803 · App. 13/655,892 · Granted Jan 20, 2015

Pharmaceutical compositions comprising DGLA and/or 15-HETrE and methods of use thereof

Inventors: Mehar Manku (Birmingham, GB); John Climax (Dublin, IE); David Coughlan (Dublin, IE)
Assignee: Dignity Sciences Limited
A61K31/202A61K9/0014A61K47/10A61K8/361A61Q17/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,936,803
App. No.
13/655,892
Granted
Jan 20, 2015
Kind
B2
Abstract

The present disclosure provides compositions comprising fatty acids, or derivatives thereof (e.g., C1-C4 esters) including, for example, DGLA, and/or 15-HETrE, used singly or in combination for the prevention and/or treatment of effects associated with UV radiation such as erythema.

Claims (10)

1. A method for preventing or reducing the occurrence of erythema on at least one area of the skin of a subject, the method comprising: topically applying a therapeutically effective amount of a composition comprising DGLA or 15-HETrE to the at least one area of skin of the subject.

2. The method of claim 1 , wherein the composition comprises about 1.0 wt. % DGLA to about 20 wt. % DGLA.

3. The method of claim 2 , wherein the composition comprises about 10 wt. % DGLA, about 1.0 wt. % DGLA, or about 0.1 wt. % DGLA.

4. The method of claim 1 , wherein the composition comprises about 0.1 wt. % to about 50 wt. % 15-HETrE.

5. The method of claim 4 , wherein the composition comprises about 10 wt. % 15-HETrE, about 1.0 wt. % 15-HETrE, about 0.1 wt. % 15-HETrE, or about 0.01 wt. % 15-HETrE.

6. The method of claim 1 , wherein the erythema is caused by exposure to UV radiation.

7. The method of claim 1 , wherein the composition is topically applied to at least one area of the skin prior to exposure of the subject to UV radiation.

8. The method of claim 1 , wherein the composition is applied to the skin on a face, arms, torso, or legs.

9. The method of claim 1 , wherein the composition further comprises a sunscreen active agent.

10. The method of claim 9 , wherein the sunscreen active agent is a UV blocker, UV absorber, or UV scattering agent.

Assignments (2)
CHANGE OF NAME Recorded Jul 31, 2017
From: DIGNITY SCIENCES LIMITED
To: DS BIOPHARMA LIMITED
Reel/Frame 043147/0143 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 22, 2013
From: MANKU, MEHAR; CLIMAX, JOHN; COUGHLAN, DAVID
To: DIGNITY SCIENCES LIMITED
Reel/Frame 029672/0445 →
Continuity (2)
Continuation 61549022 · Oct 19, 2011
Related Publication 20130101533A1 · Apr 25, 2013